Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 12, 2014, Pages 3393-3400

  De Lastours, Victoire ^a,b,c   Chau, Françoise ^b,c   Roy, Carine ^a   Larroque, Beatrice ^a   Fantin, Bruno ^a,b,c  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

FQs; Hospitalization; Resistant

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ABDOMINAL INFECTION; ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BONE AND JOINT INFECTIONS; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; ESCHERICHIA COLI; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROFLORA; MIDDLE AGED; NONHUMAN; NOSE SMEAR; PROSPECTIVE STUDY; RECTUM; RESPIRATORY TRACT INFECTION; RISK FACTOR; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; THROAT CULTURE; TREATMENT DURATION; URINARY TRACT INFECTION; AGED; BACTERIAL INFECTIONS; BACTERIUM; COHORT ANALYSIS; DRUG EFFECTS; HETEROZYGOTE; HOSPITAL; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; NOSE MUCOSA; PHARYNX; PREVALENCE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CARRIER STATE; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HOSPITALS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NASAL MUCOSA; PHARYNX; PREVALENCE; PROSPECTIVE STUDIES; RECTUM;

EID: 84937231988     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku283     Document Type: Article

References (30)

1. Andremont A, Brun-Buisson C, Struelens M. Evaluating and predicting the ecologic impact of antibiotics. Clin Microbiol Infect 2001; 7 Suppl 5: 1-6.
2. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101-14.
3. Andremont A. Role of the commensal flora in the spread of bacterial resistance: the invisible collateral damage of antibiotic treatments. ASM News 2003; 69: 601-7.
4. Janoir C, Podglajen I, Kitzis MD et al. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. J Infect Dis 1999; 180: 555-8.
5. Fantin B, Duval X, Massias L et al. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis 2009; 200: 390-8.
6. BrumfittW, Franklin I, Grady D et al. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 1984; 26: 757-61.
7. Pecquet S, Ravoire S, Andremont A. Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers. J Antimicrob Chemother 1990; 26: 125-9.
8. Darouiche R, Perkins B, Musher D et al. Levels of rifampin and ciprofloxacin in nasal secretions: correlation with MIC90 and eradication of nasopharyngeal carriage of bacteria. J Infect Dis 1990; 162: 1124-7.
9. Edlund C, Nord CE. Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections. J Antimicrob Chemother 2000; 46 Suppl 1: 41-8; discussion 63-65.
10. De Lastours V, Chau F, Tubach F et al. Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission. Antimicrob Agents Chemother 2010; 54: 5193-200.
11. Lautenbach E, Metlay JP, Mao X et al. The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin Infect Dis 2010; 51: 280-5.
12. Sommer MOA, Church GM, Dantas G. The human microbiome harbors a diverse reservoir of antibiotic resistance genes. Virulence 2010; 1: 299-303.
13. De Lastours V, Bleibtreu A, Chau F et al. Quinolone-resistant Escherichia coli from the faecal microbiota of healthy volunteers after ciprofloxacin exposure are highly adapted to a commensal lifestyle. J Antimicrob Chemother 2013; 69: 761-8.
14. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011; 108: 4554-61.
15. Vollaard EJ, Clasener HA. Colonization resistance. Antimicrob Agents Chemother 1994; 38: 409-14.
16. Han JH, Bilker WB, Nachamkin I et al. Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility. Infect Control Hosp Epidemiol 2013; 34: 1070-6.
17. Owens RC Jr, Johnson JR, Stogsdill P et al. Community transmission in the United States of a CTX-M-15-producing sequence type ST131 Escherichia coli strain resulting in death. J Clin Microbiol 2011; 49: 3406-8.
18. Marshall B, Petrowski D, Levy SB. Inter-and intraspecies spread of Escherichia coli in a farm environment in the absence of antibiotic usage. Proc Natl Acad Sci USA 1990; 87: 6609-13.
19. Walson JL, Marshall B, Pokhrel BM et al. Carriage of antibiotic-resistant fecal bacteria in Nepal reflects proximity to Kathmandu. J Infect Dis 2001; 184: 1163-9.
20. Ruimy R, Brisabois A, Bernede C et al. Organic and conventional fruits and vegetables contain equivalent counts of Gram-negative bacteria expressing resistance to antibacterial agents. Environ Microbiol 2010; 12: 608-15.
21. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol 2004; 12: 412-6.
22. De Lastours V, Cambau E, Guillard Tet al. Diversity of individual dynamic patterns of emergence of resistance to quinolones in Escherichia coli from the fecal flora of healthy volunteers exposed to ciprofloxacin. J Infect Dis 2012; 206: 1399-406.
23. Munier A-L, De Lastours V, Barbier F et al. Dynamics of the emergence of quinolone resistance in staphylococci from the nasal microbiota of patients treated by fluoroquinolones. In: Abstracts of the Fifty-second International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2012. Abstract C2-1399. American Society for Microbiology, Washington, DC, USA.
24. Lautenbach E, Fishman NO, Metlay JP et al. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis 2006; 194: 79-85.
25. Lepelletier D, Caroff N, Riochet D et al. Risk-factors for gastrointestinal colonisation with resistant Enterobacteriaceae among hospitalised patients: a prospective study. Clin Microbiol Infect 2006; 12: 974-9.
26. Maslow JN, Lee B, Lautenbach E. Fluoroquinolone-resistant Escherichia coli carriage in long-term care facility. Emerging Infect Dis 2005; 11: 889-94.
27. Lautenbach E, Metlay JP,Weiner MG et al. Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009; 30: 18-24.
28. Guerin F, Varon E, Hoï AB et al. Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci. Antimicrob Agents Chemother 2000; 44: 2197-200.
29. Barbier F, Ruppé E, Hernandez D et al. Methicillin-resistant coagulasenegative staphylococci in the community: high homology of SCCmec IVa between Staphylococcus epidermidis and major clones of methicillinresistant Staphylococcus aureus. J Infect Dis 2010; 202: 270-81.
30. Ruppé E, Barbier F, Mesli Y et al. Diversity of staphylococcal cassette chromosome mec structures in methicillin-resistant Staphylococcus epidermidis and Staphylococcus haemolyticus strains among outpatients from four countries. Antimicrob Agents Chemother 2009; 53: 442-9.